Blair William & Co. IL Lowers Position in DexCom, Inc. $DXCM

Key Points

• Blair William & Co. IL reduced its stake in DexCom, Inc. by 1.4% during the second quarter, now owning approximately 0.56% of the company, valued at around $192.74 million.
• DexCom reported a 15.2% increase in quarterly revenue year-over-year, reaching $1.16 billion and exceeding analyst expectations.
• Analysts have varied target prices for DexCom, with Goldman Sachs lowering their price objective from $104.00 to $89.00 while maintaining a "buy" rating on the stock.

Blair William & Co. IL lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,208,044 shares of the medical device company's stock after selling 30,519 shares during the quarter. Blair William & Co. IL owned about 0.56% of DexCom worth $192,740,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC increased its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after buying an additional 11,946 shares during the last quarter. Merit Financial Group LLC grew its position in DexCom by 102.3% in the first quarter. Merit Financial Group LLC now owns 5,933 shares of the medical device company's stock worth $405,000 after acquiring an additional 3,000 shares in the last quarter. Wedmont Private Capital bought a new position in DexCom in the first quarter valued at $214,000. Park Avenue Securities LLC raised its position in DexCom by 35.5% during the first quarter. Park Avenue Securities LLC now owns 18,086 shares of the medical device company's stock valued at $1,235,000 after purchasing an additional 4,739 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after purchasing an additional 702 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of DXCM stock opened at $67.78 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The business's 50 day moving average price is $74.96 and its 200-day moving average price is $77.73. The firm has a market cap of $26.58 billion, a P/E ratio of 47.07, a P/E/G ratio of 1.38 and a beta of 1.47. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period last year, the company posted $0.43 EPS. The company's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kyle Malady sold 667 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director directly owned 22,667 shares of the company's stock, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,849 shares of company stock valued at $564,733. Insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DXCM. The Goldman Sachs Group reduced their price objective on DexCom from $104.00 to $89.00 and set a "buy" rating on the stock in a research report on Wednesday, October 1st. Morgan Stanley increased their price target on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Citigroup lowered their price objective on shares of DexCom from $105.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday. Oppenheimer lowered shares of DexCom from an "outperform" rating to a "market perform" rating in a report on Monday, September 8th. Finally, Robert W. Baird decreased their target price on shares of DexCom from $112.00 to $90.00 and set an "outperform" rating on the stock in a research report on Friday, September 26th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, DexCom currently has an average rating of "Moderate Buy" and an average price target of $97.42.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.